{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:32:44Z","timestamp":1792661564232,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.eururo.2012.02.036","type":"journal-article","created":{"date-parts":[[2012,2,24]],"date-time":"2012-02-24T22:16:53Z","timestamp":1330121813000},"page":"816-830","source":"Crossref","is-referenced-by-count":152,"title":["Anticholinergic Drugs for Adult Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"62","author":[{"given":"Priya","family":"Madhuvrata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Hasafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdel-Fattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2012.02.036_bib0005","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2012.02.036_bib0010","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/01.phm.0000219229.92056.c2","article-title":"Pharmacotherapy for neurogenic detrusor overactivity","volume":"85","author":"Chancellor","year":"2006","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.eururo.2012.02.036_bib0015","unstructured":"Pannek J, St\u00f6hrer M, Blok B, et al. Guidelines on neurogenic lower urinary tract dysfunction. Arnhem, the Netherlands: European Association of Urology; 2011."},{"key":"10.1016\/j.eururo.2012.02.036_bib0020","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.eururo.2008.01.007","article-title":"Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects","volume":"53","author":"Amend","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.02.036_bib0025","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.juro.2009.05.038","article-title":"Combination drug therapy improves compliance of the neurogenic bladder","volume":"182","author":"Cameron","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.02.036_bib0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analysis of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2012.02.036_bib0035","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/(SICI)1097-0258(19970415)16:7<753::AID-SIM494>3.0.CO;2-G","article-title":"Incorporating variability in estimates of heterogeneity in the random effects model in meta-analysis","volume":"16","author":"Biggerstaff","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.eururo.2012.02.036_bib0040","unstructured":"Abrams P, Jackson S, Mattiason K, et al. A randomised, double blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia [abstract]. Presented at: 26th annual meeting of the International Continence Society; August 27\u201330, 1996; Athens, Greece."},{"key":"10.1016\/j.eururo.2012.02.036_bib0045","first-page":"A190","article-title":"The effect of darifenacin on neurogenic detrusor overactivity in patients with spinal cord injury","volume":"22","author":"Bycroft","year":"2003","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2012.02.036_bib0050","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00005392-200102000-00032","article-title":"Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens","volume":"165","author":"Di Stasi","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.02.036_bib0055","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/S0022-5347(05)65540-1","article-title":"Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin","volume":"166","author":"Di Stasi","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.02.036_bib0060","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/10790268.2004.11753751","article-title":"Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity","volume":"27","author":"Ethans","year":"2004","journal-title":"Spinal Cord Med"},{"key":"10.1016\/j.eururo.2012.02.036_bib0065","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.juro.2006.08.099","article-title":"Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial","volume":"177","author":"Fader","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.02.036_bib0070","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0022-5347(17)45940-4","article-title":"Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia","volume":"135","author":"Gajewski","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.02.036_bib0075","first-page":"209","article-title":"Treatment of detrusor hyperreflexia in multiple sclerosis; a double blind, crossover trial comparing methantheline bromide, flavoxate chloride and meladrazine tartarate","volume":"32","author":"Hebjorn","year":"1977","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2012.02.036_bib0080","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1464-410X.1995.tb07264.x","article-title":"Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia","volume":"75","author":"Madersbacher","year":"1995","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2012.02.036_bib0085","first-page":"447","article-title":"Clinical and urodynamic effects of oral propiverine therapy in neurogenic urinary incontinence: a multicentre dose-optimizing study [in German]","volume":"33","author":"Mazur","year":"1994","journal-title":"Urologe\u2014Ausgabe A"},{"key":"10.1016\/j.eururo.2012.02.036_bib0090","doi-asserted-by":"crossref","first-page":"623","DOI":"10.5414\/CPP44623","article-title":"Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients?","volume":"44","author":"Menarini","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.eururo.2012.02.036_bib0095","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000282207","article-title":"Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries: a multicentre placebo-controlled double-blind trial","volume":"47","author":"St\u00f6hrer","year":"1991","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2012.02.036_bib0100","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.sc.3100750","article-title":"Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia\u2014a double-blind, placebo-controlled clinical trial","volume":"37","author":"St\u00f6hrer","year":"1999","journal-title":"Spinal Cord"},{"key":"10.1016\/j.eururo.2012.02.036_bib0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.eururo.2006.03.016","article-title":"Propiverine compared to oxybutynin in neurogenic detrusor overactivity \u2013 results of a randomized, double-blind, multicenter clinical study","volume":"51","author":"St\u00f6hrer","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.02.036_bib0110","article-title":"Efficacy and tolerability of propiverine hydrochloride extended release compared to immediate release in patients with neurogenic detrusor overactivity","volume":"432","author":"St\u00f6hrer","year":"2009","journal-title":"International Continence Society abstract"},{"key":"10.1016\/j.eururo.2012.02.036_bib0115","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<499::AID-NAU6>3.0.CO;2-8","article-title":"Dose-ranging study of tolterodine in patients with detrusor hyperreflexia","volume":"17","author":"Van Kerrebroeck","year":"1998","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2012.02.036_bib0120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/003655902317259319","article-title":"Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity","volume":"36","author":"Lehtoranta","year":"2002","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2012.02.036_bib0125","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2165\/00044011-200121080-00005","article-title":"Randomised, double-blind, placebo-controlled study on the efficacy and tolerance of trospium chloride in patients with motor urge incontinence","volume":"21","author":"Ulshofer","year":"2001","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.eururo.2012.02.036_bib0135","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1464-410x.2000.00623.x","article-title":"A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10mg once daily) with conventional oxybutynin tablets (5mg twice daily) in patients whose symptoms were stabilized on 5mg twice daily of oxybutynin","volume":"85","author":"Birns","year":"2000","journal-title":"BJU Int"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2012.02.036_bib0140","article-title":"Trospium chloride versus oxybutynin in the treatment of bladder neurological disorders: a double blind randomised clinical trial [abstract 44]","volume":"80","author":"Osca","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2012.02.036_bib0145","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.urology.2009.05.008","article-title":"Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study","volume":"74","author":"Kennelly","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.02.036_bib0150","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/10790268.2003.11753678","article-title":"Effect of controlled release oxybutynin on neurogenic bladder function in spinal cord injury","volume":"26","author":"O\u2019Leary","year":"2003","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.eururo.2012.02.036_bib0155","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/nau.20289","article-title":"Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage","volume":"25","author":"Horstmann","year":"2006","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2012.02.036_bib0160","unstructured":"A randomized, double blind, double dummy, placebo controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10mg once daily) against placebo and oxybutynin hydrochloride (5mg three times daily) in the treatment of subjects with neurogenic detrusor overactivity [identifier NCT00629642]. ClinicalTrials.gov Web site. http:\/\/clinicaltrials.gov\/show\/NCT00629642. Accessed December 2011."},{"key":"10.1016\/j.eururo.2012.02.036_bib0165","unstructured":"Hassouna M. Comparative study of the efficacy and safety of muscarinic M3 receptors antagonists in the treatment of neurogenic detrusor overactivity [identifier NCT00800462]. ClinicalTrials.gov Web site. http:\/\/clinicaltrials.gov\/show\/NCT00800462. Accessed December 2011."},{"key":"10.1016\/j.eururo.2012.02.036_bib0170","first-page":"CD003781","article-title":"Anticholinergic drugs versus placebo for overactive bladder syndrome in adults","volume":"4","author":"Nabi","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2012.02.036_bib0200","first-page":"CD004193","article-title":"Anticholinergics for urinary symptoms in multiple sclerosis","volume":"1","author":"Nicholas","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2012.02.036_bib0175","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.02.036_bib0180","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2008.06.080","article-title":"A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder","volume":"54","author":"Novara","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.02.036_bib0195","first-page":"CD005429","article-title":"Which anticholinergic drug for overactive bladder symptoms in adults","volume":"3","author":"Hay-Smith","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2012.02.036_bib0205","unstructured":"St\u00f6hrer M, M\u00fcrtz G, Madersbacher H. Neurogenic detrusor overactivity in adults: a review of the efficacy, tolerability and safety of oral antimuscarinics [abstract 197]. Presented at: 3rd combined annual meeting of the International Continence Society and the International Urogynecological Association; August 23\u201327, 2010; Toronto, Canada."}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812002308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812002308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T04:11:05Z","timestamp":1561349465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283812002308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0302283812002308"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2012.02.036","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}